2 Information about atezolizumab

In July 2018 the European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. For more information, see the summary of product characteristics for atezolizumab.

Marketing authorisation indication

2.1 Atezolizumab (Tecentriq, Roche) has a marketing authorisation for 'the treatment of adult patients with locally advanced or metastatic urothelial carcinoma:

  • after prior platinum-containing chemotherapy, or

  • who are considered cisplatin ineligible and whose tumours have a PD-L1 expression of 5% or more'.

Dosage in the marketing authorisation

2.2 1,200 mg by intravenous infusion every 3 weeks.


2.3 A 1,200 mg vial costs £3,807.69 excluding VAT. The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)